TRIFECTA CELL INFUSION Trademark

Trademark Overview


On Monday, March 3, 2025, a trademark application was filed for TRIFECTA CELL INFUSION with the United States Patent and Trademark Office. The USPTO has given the TRIFECTA CELL INFUSION trademark a serial number of 99064085. The federal status of this trademark filing is SUSPENSION LETTER - MAILED as of Monday, November 17, 2025. This trademark is owned by ImmunityBio, Inc.. The TRIFECTA CELL INFUSION trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical preparations and substances for the treatment of human diseases and animal diseases, namely, bladder cancer, prostate cancer, blood cancers, brain cancers, lung cancer, liver cancer, colorectal cancer, pancreatic cancer, non-cancerous neoplasia, immunologic-related diseases, immunologic dysfunction, lymphopenia, genetic diseases, Lynch syndrome, HIV, papillomavirus, infections, viral infections, respiratory infections and blood infections, autoimmune diseases, infectious diseases and cancer for scientific, clinical, medicinal, therapeutic, and diagnostic purposes; pharmaceutical preparations and substances for the prevention and treatment of human diseases and animal diseases, namely, bladder cancer, prostate cancer, blood cancers, brain cancers, lung cancer, liver cancer, colorectal cancer, pancreatic cancer, non-cancerous neoplasia, immunologic-related diseases, immunologic dysfunction, lymphopenia, genetic diseases, Lynch syndrome, HIV, papillomavirus, infections, vir...
trifecta cell infusion

General Information


Serial Number99064085
Word MarkTRIFECTA CELL INFUSION
Filing DateMonday, March 3, 2025
Status653 - SUSPENSION LETTER - MAILED
Status DateMonday, November 17, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and Servicespharmaceutical preparations and substances for the treatment of human diseases and animal diseases, namely, bladder cancer, prostate cancer, blood cancers, brain cancers, lung cancer, liver cancer, colorectal cancer, pancreatic cancer, non-cancerous neoplasia, immunologic-related diseases, immunologic dysfunction, lymphopenia, genetic diseases, Lynch syndrome, HIV, papillomavirus, infections, viral infections, respiratory infections and blood infections, autoimmune diseases, infectious diseases and cancer for scientific, clinical, medicinal, therapeutic, and diagnostic purposes; pharmaceutical preparations and substances for the prevention and treatment of human diseases and animal diseases, namely, bladder cancer, prostate cancer, blood cancers, brain cancers, lung cancer, liver cancer, colorectal cancer, pancreatic cancer, non-cancerous neoplasia, immunologic-related diseases, immunologic dysfunction, lymphopenia, genetic diseases, Lynch syndrome, HIV, papillomavirus, infections, viral infections, respiratory infections and blood infections, autoimmune diseases, infectious diseases and cancer; pharmaceutical and biological preparations for use in targeted immunotherapy for the treatment of human diseases and animal diseases, namely, bladder cancer, prostate cancer, blood cancers, brain cancers, lung cancer, liver cancer, colorectal cancer, pancreatic cancer, non-cancerous neoplasia, immunologic-related diseases, immunologic dysfunction, lymphopenia, genetic diseases, Lynch syndrome, HIV, papillomavirus, infections, viral infections, respiratory infections and blood infections, autoimmune diseases, infectious diseases and cancer; pharmaceutical preparations and substances containing autologous or allogeneic cells for the treatment of human diseases and animal diseases in the nature of cancer, non-cancerous neoplasia, immunologic-related diseases, immunologic dysfunction, autoimmune diseases and infectious diseases; biologic in the nature of pharmaceutical preparations for the treatment of autoimmune diseases, infectious diseases, and cancer, namely, cell-derived preparations, cell therapies, monoclonal antibodies, cytokines, immune modulators, antibodies, fusion proteins, peptide and cytokine biologics, and natural killer cell derived preparations for clinical, medicinal, therapeutic, and veterinary purposes; kits comprising cell cultures being biological preparations for medical purposes and reagents for medical use and also including printed instructions, for use in the treatment and prevention of bladder cancer, prostate cancer, blood cancers, brain cancers, lung cancer, liver cancer, colorectal cancer, pancreatic cancer, non-cancerous neoplasia, immunologic-related diseases, immunologic dysfunction, lymphopenia, genetic diseases, Lynch syndrome, HIV, papillomavirus, infections, viral infections, respiratory infections and blood infections, non-cancerous neoplasia, immunologic-related diseases, immunologic dysfunction, autoimmune diseases, infectious diseases, and cancer for clinical, medicinal, therapeutic and veterinary purposes; all of the aforementioned excluding preparations and substances used in connection with implant material
NOT AVAILABLE"CELL INFUSION"

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, March 3, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameImmunityBio, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121

Trademark Events


Event DateEvent Description
Monday, March 3, 2025NEW APPLICATION ENTERED
Monday, March 3, 2025APPLICATION FILING RECEIPT MAILED
Monday, March 3, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, August 5, 2025ASSIGNED TO EXAMINER
Thursday, August 7, 2025NON-FINAL ACTION WRITTEN
Thursday, August 7, 2025NON-FINAL ACTION E-MAILED
Thursday, August 7, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, October 27, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, October 27, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, October 27, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, November 17, 2025SUSPENSION LETTER WRITTEN
Monday, November 17, 2025LETTER OF SUSPENSION E-MAILED
Monday, November 17, 2025NOTIFICATION OF LETTER OF SUSPENSION E-MAILED